The management of aggressive pituitary tumours remains a challenge, however, the recent identification of temozolomide as a chemotherapeutic agent with significant efficacy against these tumours has heralded a new therapeutic era. There has been an exponential growth in the international experience with temozolomide over the past five years, now totalling 50 published cases. Overall, 67 % of cases demonstrated a response to temozolomide. Prolactin- and adrenocorticotrophic hormone (ACTH)-secreting tumours respond more frequently than non-functioning tumours. Response is typically evident in the first three months of treatment. Adverse effects occur in almost half of patients, although the majority are mild. The expression of a DNA repair enzyme, 06-methylguanine-DNA methyltransferase (MGMT), as determined by immunohistochemistry, appears to be the primary determinant of response to temozolomide in pituitary tumours. There is suggestion that MGMT may also play a role in pituitary tumorigenesis. Over the nextfew years we will see temozolomide used earlier in the treatment algorithm of aggressive pituitary tumours, making it imperative tocollect global long-term data on its use.<\/p>\n
To view the full article in PDF or eBook formats, please click on the icons above.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"
Abstract The management of aggressive pituitary tumours remains a challenge, however, the recent identification of temozolomide as a chemotherapeutic agent with significant efficacy against these tumours has heralded a new therapeutic era. There has been an exponential growth in the international experience with temozolomide over the past five years, now totalling 50 published cases. Overall, […]<\/p>\n","protected":false},"author":65022,"featured_media":1222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","vocabulary_1-neurological-oncology"],"acf":{"wpcf-article_introduction":"","wpcf-article_abstract":"","wpcf-article_keywords":"","wpcf-article_citation_override":"European Neurological Review,<\/i> 2012;7(4):228-233 DOI: http:\/\/doi.org\/10.17925\/ENR.2012.07.04.228<\/a>","wpcf-compliance-with-ethics":"","wpcf-article_disclosure":"","wpcf-review_process":"","wpcf-authorship":"","wpcf-article_correspondence":"","wpcf-article_support":"","wpcf-open_access":"","wpcf-article_pdf":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2015\/06\/private_articles_10592_pdf_euneuro74-30-35.pdf","wpcf-article_pdf-gated":true,"wpcf-article_doi":"","wpcf-old_nid":"","wpcf-article_image":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2018\/08\/blue-brain_7.png","wpcf-editor_choice":true,"wpcf-old_author_ids":"","wpcf-article_references":"","wpcf-article_received_date":null,"wpcf-article_accepted_date":null,"wpcf-article_published_online":null,"wpcf-podcast":"","wpcf-ogg":"","wpcf-article_end_page":"233","wpcf-article_start_page":"228","wpcf-acknowledgements":"","wpcf-errata_pdf":"","wpcf-article_flipper_image":"http:\/\/touchneurology.com\/wp-content\/uploads\/sites\/3\/2016\/12\/Neuro-15_3.jpg","wpcf-corrected_online":null,"wpcf-supplementary_information":"","wpcf-article_highlight_pdf":"","data_availability":"","digital_features":""},"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/1221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/users\/65022"}],"replies":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/comments?post=1221"}],"version-history":[{"count":0,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/posts\/1221\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/1222"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=1221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/categories?post=1221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/tags?post=1221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}